Traws Pharma, Inc. (TRAW)
NASDAQ: TRAW · Real-Time Price · USD
0.8918
+0.0415 (4.88%)
At close: Jun 22, 2026, 4:00 PM EDT
0.8650
-0.0268 (-3.01%)
Pre-market: Jun 23, 2026, 7:40 AM EDT
Traws Pharma Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Traws Pharma stock have an average target of $1.00, which predicts a 12.13% increase from the current stock price of 0.89.
Price Target: $1.00 (+12.13%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Traws Pharma stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 2 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Hold Downgrades $8 → $1 | Hold | Downgrades | $8 → $1 | +12.13% | Jun 18, 2026 |
| Ladenburg Thalmann & Co. | Ladenburg Thalmann & Co. | Hold Downgrades n/a | Hold | Downgrades | n/a | n/a | Jun 15, 2026 |
Financial Forecast
Revenue This Year
n/a
from 2.79M
Decreased by -100.00%
Revenue Next Year
n/a
EPS This Year
-1.82
from -2.35
EPS Next Year
-1.98
from -1.82
EPS and Forward PE are based on non-GAAP adjusted numbers.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | ||
| Avg | n/a | ||
| Low | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -100.0% | ||
| Avg | -100.0% | ||
| Low | -100.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -1.82 | ||
| Avg | -1.82 | ||
| Low | -1.82 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |